ATIC – Anti-Oxidant Therapy in Chronic Renal Insufficiency Study

Principal contacts

Prabath W.B. Nanayakkara - Amsterdam UMC, Amsterdam, the Netherlands

Coen D. A. Stehouwer - Maastricht University Medical Centre, Maastricht, the Netherlands

Pieter M. ter Wee - Amsterdam UMC, Amsterdam, the Netherlands

Study design

The Anti-oxidant Therapy in Chronic Renal Insufficiency Study (ATIC) is a two-arm clinical trial based at seven (six nephrology and one internal medicine) outpatient clinics in Amsterdam, the Netherlands. The principal aim of the trial was to investigate the effect of Pravastatin (40mg/day), α-tocopherol (300mg/day), Folic acid (5mg/day), Pyridoxine hydrochloride (100mg/day), and Cyanocobalamin (1mg/day) versus placebo on the vascular function and structure in patients with chronic non-diabetic renal failure free from manifest arterial occlusive disease. Individuals were eligible for inclusion if they had mild-to-moderate chronic kidney disease. Written informed consent was obtained from all participants, and the study was approved by the ethical committees at each centre.

Link to study webpage – 


Key publications

Plasma asymmetric dimethylarginine (ADMA) concentration is independently associated with carotid intima-media thickness and plasma soluble vascular cell adhesion molecule-1 (sVCAM-1) concentration in patients with mild-to-moderate renal failure. Kidney Int. 2005 Nov;68(5):2230-6

Effect of a Treatment Strategy Consisting of Pravastatin, Vitamin E, and Homocysteine Lowering on Carotid Intima-Media Thickness, Endothelial Function, and Renal Function in Patients With Mild to Moderate Chronic Kidney Disease: Results From the Anti-Oxidant Therapy in Chronic Renal Insufficiency (ATIC) Study. Arch Intern Med. 2007 Jun 25;167(12):1262-70